Candidemia Clinical Trial
Official title:
Anidulafungin Population Kinetics in the Intensive Care Population
The purpose of this study is to determine the pharmacokinetics of anidulafungin in intensive care patients.
Not a lot is known about the pharmacokinetic profile of anidulafungin in IC-patients.
IC-patients are at high(er) risk for getting a systemic mould/yeast infection. Anidulafungin
is a safe echinocandin with, so far, no reported interactions and few adverse effects. Due
to this, anidulafungin is used more often on IC-wards. It is part of the national
(Netherlands) IC sepsis protocol. The factors that influence the pharmacokinetics of
anidulafungin in IC-patients has not been studied yet. Because these factors are unknown for
this population, it is necessary for this research to be done.
Any patient with an (suspected) invasive candidiasis whom is treated with anidulafunging can
be includen.
20 patients will be included from 2 different university hospital (10 each). Samples will be
taken on different days and timepoints, troughlevels on all treatment days and on treatment
day 3 and 7 more samples will be taken voor AUC calculations.
;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01982071 -
A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia
|
Phase 4 | |
| Completed |
NCT02244606 -
Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis
|
Phase 2 | |
| Completed |
NCT02163889 -
Serial Therapeutic and Antifungal Monitoring Protocol
|
||
| Not yet recruiting |
NCT01249313 -
Risk Factor and Outcome of Candidemia
|
N/A | |
| Terminated |
NCT01213823 -
Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins
|
Phase 4 | |
| Completed |
NCT00940017 -
A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects
|
Phase 4 | |
| Completed |
NCT00105144 -
Study of Micafungin in Patients With Invasive Candidiasis or Candidemia
|
Phase 3 | |
| Completed |
NCT03667690 -
Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis
|
Phase 3 | |
| Completed |
NCT03604705 -
An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia
|
Phase 2 | |
| Completed |
NCT00607763 -
Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug
|
Phase 1 | |
| Completed |
NCT00608335 -
Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug
|
Phase 1 | |
| Recruiting |
NCT04147975 -
Assessment of Assay for Rapid Identification of Bloodstream Infections From Whole Blood
|
||
| Completed |
NCT01734525 -
Negative Beta Glucan in ICU Patients
|
Phase 4 | |
| Withdrawn |
NCT01622595 -
UARK 2009-99 A Non-interventional Observational Study of Infectious Complications in Cancer Patients
|
N/A | |
| Completed |
NCT03363841 -
Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)
|
Phase 3 | |
| Completed |
NCT03799172 -
Echinocandins Versus Azoles for Candidemia Treatment
|
||
| Completed |
NCT01406093 -
Early- and Late-onset Candidemia
|
N/A | |
| Completed |
NCT00670657 -
CRITIC - Treatment of Candidemia and Invasive Candidiasis
|
Phase 4 | |
| Completed |
NCT00113191 -
Safety and Efficacy of Veronate® Versus Placebo in Preventing Nosocomial Staphylococcal Sepsis in Premature Infants
|
N/A | |
| Recruiting |
NCT04368559 -
Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation
|
Phase 3 |